TMO

Thermo Fisher Scientific Inc TMO

$532.48 -10.71 (-1.97%)

Extended · +1.37σ Grade C

+ Compare Open in Sniper

Mkt cap $196.4B

P/E 29.3

Day $531.62 – $542.02

52wk $435.27 – $643.99

Avg vol —

Beta —

Div yld —

Next earnings —

Quick read

Plain English

Thermo Fisher Scientific Inc is a healthcare company listed in the US.

TMO last traded at $532.48, down 2.0% on the day; that's in the middle part of its 52-week range ($435.27–$643.99). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.

Earnings reports are the biggest scheduled catalysts to keep an eye on, and after a strong run, watch whether the price can hold its gains on quieter days.

A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

KC1 upper, +1.27 ATR from EMA21 — no notable pattern

Long —

score 16 · tech 16 / 80 · support 0 / 20

above KC1 lower, +1.27 ATR from EMA21 · no notable pattern

· Aligned with strong uptrend (strong tailwind)

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short C

score 26 · tech 26 / 80 · support 0 / 20

KC1 upper, +1.27 ATR from EMA21 · no notable pattern

· KC1 upper stretch — light pop
· RSI hook from overbought (63)
· Stochastic bear cross in overbought

How this grade was earned

total 26 pts

Cycle position 14

Momentum 12

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Under the hood

On the latest daily bar, momentum sits mid-range (RSI 63), the trend is strong (ADX 35), and trading is light at 0.7× normal volume. On the business side, revenue is growing 6% year over year and the business keeps about 12 cents of every sales dollar as free cash.

Latest-bar indicator readings behind the grade — display-only, they don't move the letter.

Momentum · RSI

0–100 · <30 oversold

Trend strength · ADX

>25 = strong trend

Volume vs avg

0.70×

1× = average

Stretch from avg

+1.3 ATR

− below · + above

Zone touches

tests of this zone

Suggested hold

3–30

bars (≈ days)

Fundamentals at a glance

Company fundamentals for context — display-only, they don't move the grade.

Revenue growth

+6.2%

year over year

Free-cash-flow margin

12.4%

cash kept per $ of sales

Debt / equity

0.83

lower = less leveraged

P/E ratio

29.3

price ÷ yearly profit

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $172.45 (fair range $172–$360); today's price sits 210% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.

Intrinsic (DCF)

$172.45

Fair-value range

$172.45 – $359.70

Margin of safety

-210%

Verdict

Overvalued

Accounting quality Weak

✓ Positive retained earnings
✓ Gross margin 41% (pricing power)

⚠ Debt exceeds cash
⚠ Quick ratio 0.80 (fragile)
⚠ Inventory growing faster than revenue

Price implies ~21% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

TMO is a $196.4 billion company, priced at 29× last year's earnings.

Mkt cap $196.4B

P/E ttm 29.3

Fwd P/E —

Beta —

Day range $531.62 – $542.02

52w range $435.27 – $643.99

Avg vol —

RSI(2) 33.2

ROE —

Net mgn —

FCF mgn 12.4%

Debt/Eq 0.83

Div yld —

Sector Healthcare

Industry Diagnostics & Research

Next earn —

52-week range · today's price

$435.27$643.99